Shukra Medtech Limited
NSE: SHUKRAMED · Pharmaceuticals
Share price ₹84.16
close of 20 Nov 2026
Your ratios
Market cap
₹3,725 Cr
P/E ratio
84.1
EPS TTM to Sep 2026
P/B ratio
31.6
ROCE
37.0%
ROE
28.8%
Dividend yield
0.0%
as of 20 Nov 2026
1 · Overview
Overview
Price, valuation, sales and profit over the range you pick. Prices as of the last close; results as filed.
At a glance · Max
Every small chart follows the range above. Point at it to read a value; click it to open it.2 · Results
Latest result · Q2 FY27
What the last results showed. Whether management kept its word is in Pro.
Net profit ₹13.0 Cr, up 550.0% on Sep 2025
Years to March, 2015–2026, and the last 12 months · key lines
| Line | Mar 2015FY15 | Mar 2016FY16 | Mar 2017FY17 | Mar 2018FY18 | Mar 2019FY19 | Mar 2020FY20 | Mar 2021FY21 | Mar 2022FY22 | Mar 2023FY23 | Mar 2024FY24 | Mar 2025FY25 | Mar 2026FY26 | TTMto Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales₹ crore | 3 | 5change on a year before +67% | 5change on a year before 0% | 5change on a year before 0% | 6change on a year before +20% | 12change on a year before +100% | 11change on a year before -8% | 20change on a year before +82% | 59change on a year before +195% | 75change on a year before +27% | 33change on a year before -56% | 57change on a year before +73% | 113change on a year before +223% |
| Expenses₹ crore | 3 | 4 | 4 | 4 | 4 | 10 | 10 | 18 | 53 | 55 | 20 | 28 | 48 |
| Operating profit₹ crore | 0 | 1 | 1change on a year before 0% | 2change on a year before +100% | 2change on a year before 0% | 2change on a year before 0% | 1change on a year before -50% | 3change on a year before +200% | 5change on a year before +67% | 19change on a year before +280% | 13change on a year before -32% | 29change on a year before +123% | 66change on a year before +450% |
| Operating margin% of sales | -10.00% | 24.00% | 28.00% | 30.00% | 29.00% | 13.00% | 13.00% | 14.00% | 9.00% | 26.00% | 39.00% | 51.00% | 58.41% |
| Other income₹ crore | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 4 | 5 | 4 |
| Interest₹ crore | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Depreciation₹ crore | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 4 |
| Profit before tax₹ crore | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 4 | 20 | 13 | 29 | 63 |
| Tax rate% of profit before tax | 52.00% | 66.00% | 52.00% | 45.00% | 37.00% | 82.00% | -90.00% | 26.00% | 1.00% | 7.00% | 28.00% | 23.00% | |
| Net profit₹ crore | 0 | 0 | 0 | 1 | 0change on a year before -100% | 0 | 0 | 1 | 4change on a year before +300% | 19change on a year before +375% | 10change on a year before -47% | 22change on a year before +120% | 44change on a year before +300% |
| EPS₹ per share | 0.00 | 0.00 | 0.02 | 0.02change on a year before 0% | 0.02change on a year before 0% | 0.00change on a year before -100% | 0.01 | 0.02change on a year before +100% | 0.15change on a year before +650% | 0.42change on a year before +180% | 0.22change on a year before -48% | 0.50change on a year before +127% | 1.00change on a year before +285% |
| Dividend paid out% of net profit | 0.00% | 0.00% | 16.00% | 15.00% | 17.00% | 0.00% | 0.00% | 10.00% | 4.00% | 6.00% | 5.00% | 2.00% |
Small figure: change on the year before (TTM: on the 12 months to Sep 2025). TTM = the four quarters to Sep 2026.
Filed only on the standalone basis, so shown from it: Depreciation, Dividend paid out, EPS, Expenses, Interest, Net profit, Operating margin, Operating profit, Other income, Profit before tax, Sales, Sales growth, Tax rate.
The last 13 quarters, Sep 2023 to Sep 2026 · key lines
| Line | Sep 2023Q2 FY24 | Dec 2023Q3 FY24 | Mar 2024Q4 FY24 | Jun 2024Q1 FY25 | Sep 2024Q2 FY25 | Dec 2024Q3 FY25 | Mar 2025Q4 FY25 | Jun 2025Q1 FY26 | Sep 2025Q2 FY26 | Dec 2025Q3 FY26 | Mar 2026Q4 FY26 | Jun 2026Q1 FY27 | Sep 2026Q2 FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales₹ crore | 25 | 19 | 11 | 3 | 6 | 11 | 13 | 5 | 6 | 39change on a year before +255% | 6change on a year before -54% | 24change on a year before +380% | 44change on a year before +633% |
| Expenses₹ crore | 20 | 9 | 6 | 2 | 5 | 7 | 6 | 4 | 6 | 12 | 6 | 4 | 26 |
| Operating profit₹ crore | 5 | 10 | 4 | 1 | 1 | 4 | 7 | 1 | 0 | 27change on a year before +575% | 1change on a year before -86% | 19change on a year before +1800% | 19 |
| Operating margin% of sales | 21.00% | 51.00% | 41.00% | 25.00% | 12.00% | 37.00% | 55.00% | 24.00% | -7.00% | 69.00% | 11.00% | 81.00% | 42.00% |
| Other income₹ crore | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 |
| Depreciation₹ crore | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax₹ crore | 5 | 10 | 5 | 1 | 1 | 4 | 8 | 1 | 0 | 27 | 0 | 18 | 18 |
| Tax rate% of profit before tax | 0.00% | 1.00% | 24.00% | 41.00% | 39.00% | 23.00% | 29.00% | 26.00% | -1090.00% | 24.00% | 553.00% | 29.00% | 29.00% |
| Net profit₹ crore | 5 | 9 | 4 | 0 | 1 | 3 | 5 | 1 | 2 | 20change on a year before +567% | -2change on a year before -140% | 13change on a year before +1200% | 13change on a year before +550% |
| EPS₹ per share | 0.11 | 0.22 | 0.09 | 0.01 | 0.01 | 0.07 | 0.12 | 0.02 | 0.05 | 0.46change on a year before +557% | -0.04change on a year before -133% | 0.29change on a year before +1350% | 0.29change on a year before +480% |
Small figure: change on the same quarter a year earlier. Lines that are 0 or blank in every column are not shown.
Filed only on the standalone basis, so shown from it: Depreciation, EPS, Expenses, Interest, Net profit, Operating margin, Operating profit, Other income, Profit before tax, Sales, Tax rate, YoY Sales growth.
Sales and profit: growth a year, compounded, to Mar 2026; TTM is the last 12 months. Share price: to the latest close. A span can cross a demerger or an acquisition.
Sales
a year, compounded
- 3 years
- -1%
- TTM
- 222%
3 years: base year from the standalone accounts; the consolidated accounts start later.
Profit
a year, compounded
- TTM
- 300%
Share price
a year, compounded
- 10 years
- 70%
- 5 years
- 212%
- 3 years
- 231%
- 1 year
- 97%
Return on equity
average over the span
- Last year
- 29%
3 · Quality & value
Answers
The questions investors ask most, each answered first in one line, then shown. From the company's own numbers.
How fast it has been growing
Our sales figures for this company step up at Jun 2026 and we hold nothing that says why, so we cannot honestly quote a growth rate across it.
Whether it grew faster than its sector
We do not have three full years of its sales yet, so there is nothing to compare with its sector.
Room to re-rate, or risk of de-rating
Too little price history yet to compare it with its own past.
Whether growth justifies the valuation
It has no steady three-year profit record yet, so growth cannot be weighed against the price.
How it compares with its peers
Against companies the exchange files under the same label (Pharmaceuticals), it ranks 10 of 132 on returns, 3 of 132 on margin.
A longer bar is a better rank.
What makes it hard to beat — and is that still true?
A wide advantage: it earns 37.0% on capital, ahead of 92% of companies filed under the same label.
Whether its growth pays for itself
Only 2 years of matching accounts on file — too few to judge this yet.
Peers here are the 132 companies the exchange files under the same label (Pharmaceuticals). That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Business score & profit checks
How strong the business is, and whether its profit is real cash. Facts only, not advice.
Business score
59 out of 100
How strong the business is, in one number. Last changed 20 Nov 2026.
Profit checks: is the profit real cash?
6 of 7 checks clear
2 of 9 checks could not be run.
Simple checks on the accounts. Which one is flagged is in Pro.
Key numbers & peers
Grouped by topic. Each number says what period it is for.
Price
- Market cap
- ₹3,725 Cr
- Prev close
- ₹84.16
- 52w High
- —
- 52w Low
- —
- Beta
- —
- Price CAGR 1y
- 97.0%
- Price CAGR 3y
- 231.0%
- Price CAGR 5y
- 212.0%
- Price CAGR 10y
- 70.0%
Valuation
- P/E ratioEPS TTM to Sep 2026
- 84.1
- Industry P/E
- 34.7
- P/B ratio
- 31.6
- EV / EBITDA
- 56.4
- Enterprise value
- ₹3,724 Cr
- PEG ratio
- —
- Dividend yield
- 0.0%
Returns
- ROCE
- 37.0%
- ROCE 5y average
- 26.5%
- ROE
- 28.8%
- ROE 3y average
- —
- ROE last year
- 29.0%
- Return on assets
- 18.8%
Sales, profit & margins
- Annual revenue
- ₹57.0 Cr
- Annual profit
- ₹22.0 Cr
- EPS
- ₹0.5
- Operating margin
- 51.0%
- Net profit margin
- 38.6%
- EBITDA margin
- 50.9%
- Sales latest quarterSep 2026 quarter
- ₹44.0 Cr
- Profit latest quarterSep 2026 quarter
- ₹13.0 Cr
- OPM latest quarterSep 2026 quarter
- 42.0%
Growth a year
- Sales growth 3y
- -1.1%
- Sales growth 5y
- —
- Sales growth TTM
- 222.0%
- Profit growth 3y
- —
- Profit growth 5y
- —
- Profit growth TTM
- 300.0%
- YoY quarterly sales growthSep 2026 vs Sep 2025
- 633.3%
- YoY quarterly profit growthSep 2026 vs Sep 2025
- 550.0%
Balance sheet
- Book Value
- ₹2.7
- Face Value
- ₹1.0
- Borrowings
- ₹5.00 Cr
- Total debt
- ₹22.0 Cr
- Total cash
- ₹11.0 Cr
- Net cashas of 31 Mar 2026
- ₹1.00 Cr
- Debt / Equity
- 0.2
- Interest coverage
- 30.0
- Reserves / Equity
- 1.0
Cash & payout
- Operating cash flow
- ₹3.00 Cr
- Free cash flow
- -₹13.0 Cr
- FCF yield
- -0.4%
- Net cash flow
- -₹6.00 Cr
- Dividend payout
- 2.0%
Holdings
- Promoter holding
- 51.2%
- FII holding
- 0.4%
- DII holding
- 0.2%
- Public holding
- 48.2%
Enterprise value, step by step
What buying the whole company would cost: its market value, less the cash it holds over its debt. Net cash from the balance sheet of 31 Mar 2026.
- Market cap₹3,725 Cr
- −Net cash₹1.00 Cr
- =Enterprise value₹3,724 Cr
4 · Balance sheet & cash
Balance sheet
What the company owns and what it owes, at each year end and at the filed half-years. ₹ crore.
At Mar 2026: ₹117 cr of assets, and who funds them
Shareholders’ own money funds 77% of it; borrowings 4%.
What it owns
- Fixed assets ₹22.0 cr 19%
- Being built ₹12.0 cr 10%
- Everything else ₹83.0 cr 71%
Who funds it
- Shareholders’ money ₹90.0 cr 77%
- Borrowings ₹5.00 cr 4%
- Everything else ₹22.0 cr 19%
Each year end. Newest year end shaded.
| Line, ₹ crore | Mar 2025FY25 | Mar 2026FY26 |
|---|---|---|
| Equity capital | 44 | 44 |
| Reserves | 19 | 46 |
| Borrowings | 4 | 5 |
| Other liabilities | 20 | 23 |
| Total funding | 87 | 117 |
| Fixed assets | 19 | 22 |
| Being built (CWIP) | 2 | 12 |
| Other assetsreceivables, cash, rest | 65 | 84 |
| Total assets | 87 | 117 |
Cash flows
Real money coming in and going out — from the business, from investments and from loans. ₹ crore.
Pick a period to see where its cash went.
In words
- The business brought in ₹3.00 cr, 10% of its operating profit before tax.
- It put ₹14.0 cr into assets and investments.
- It raised ₹5.00 cr from shareholders and lenders.
- Cash in hand fell by ₹6.00 cr. Free cash flow: −₹13.0 cr.
| Line, ₹ crore | Mar 2025FY25 | Mar 2026FY26 |
|---|---|---|
| From the business | 8 | 3 |
| From investing | -1 | -14 |
| From financingdividends, buybacks, loans | -5 | 5 |
| Net change in cash | 2 | -6 |
| Free cash flow | 5 | -13 |
| Cash ÷ operating profitbefore tax | 62.00% | 10.00% |
Free cash flow = cash from the business − spending on assets + what assets sold fetched; the same rule for years and half-years.
Efficiency ratios
How fast customers pay and how well capital earns. Each year, Mar 2015 to Mar 2026.
Debtor days
147 days
Days customers take to pay. Lower is faster.
147 days in FY26, against 100 days in FY25. Over these 12 years: 71 days (FY16) to 345 days (FY19).
Inventory days
320 days
Days stock sits before it is sold.
320 days in FY26, against 447 days in FY25. Over these 12 years: 19 days (FY24) to 554 days (FY15).
Days payable
232 days
Days it takes to pay its suppliers.
232 days in FY26, against 414 days in FY25. Over these 12 years: 59 days (FY24) to 1161 days (FY19).
Cash conversion cycle
236 days
Debtor days plus inventory days, less days payable.
236 days in FY26, against 131 days in FY25. Over these 12 years: −717 days (FY19) to 335 days (FY15).
Working capital days
352 days
Days of sales tied up in running the business.
352 days in FY26, against 403 days in FY25. Over these 12 years: 41 days (FY23) to 758 days (FY15).
Return on capital (ROCE)
37%
Operating profit on the capital used.
37% in FY26. Over these 11 years: −1% (FY15) to 44% (FY24).
Filed only on the standalone basis, so shown from it: Cash Conversion Cycle, Days Payable, Debtor Days, Inventory Days, ROCE %, Working Capital Days.
5 · Owners & payouts
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividend a share, by the year of its ex-date
No dividend on record.
Share of profit paid as dividend
Each year, Mar 2015 to Mar 2026.
Splits, bonuses & buybacks
None on record.
Big trades by funds and insiders
None listed for this company.
6 · Price & trading
Open interestPRO
Where option traders are positioned on this stock.
7 · Business
About
What the company is, from our own records: where it sits, where its revenue comes from, and where it works.
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Symbol
- SHUKRAMED
- ISIN
- INE551C01044
Industry numbers
The numbers that matter most in this industry, from the company's own filings and earnings calls. Each one says its period.
Revenue and margin
- EBIT marginSep 2026 quarter40.91%
Working capital
- Days sales outstanding12 months to Sep 2026126 days
Profit quality
- Other income shareSep 2026 quarter5.56%
Returns
- RoE12 months to Mar 202627.45%
- RoA12 months to Mar 202620.59%
- Sales to net block12 months to Sep 20265.38x
Leverage
- Net debt to EBITDA12 months to Mar 2026-0.03x
Growth
- Revenue growth (YoY)Sep 2026 quarter633.33%
Capex
- CapexFY to Mar 2026₹16.0 Cr
- Capex to revenueFY to Mar 202628.07%
How they have moved
EBIT margin · quarterly
Source: Computed from the filings
| Sep 26 | 40.91% | Computed from the filings |
| Jun 26 | — | not filed |
| Mar 26 | 0.00% | Computed from the filings |
| Dec 25 | — | not filed |
Other income share · quarterly
Source: Computed from the filings
| Sep 26 | 5.56% | Computed from the filings |
| Jun 26 | 5.56% | Computed from the filings |
| Mar 26 | — | not filed |
| Dec 25 | 3.70% | Computed from the filings |
Revenue growth (YoY) · quarterly
Source: Computed from the filings
| Sep 26 | 633.33% | Computed from the filings |
| Jun 26 | 380.00% | Computed from the filings |
| Mar 26 | -53.85% | Computed from the filings |
| Dec 25 | 254.55% | Computed from the filings |
Capex (fiscal year) · yearly
Source: Computed from the filings
| FY26 | ₹16.0 Cr | Computed from the filings |
| FY25 | ₹3.00 Cr | Computed from the filings |
Capex to revenue (fiscal year) · yearly
Source: Computed from the filings
| FY26 | 28.07% | Computed from the filings |
| FY25 | 9.09% | Computed from the filings |
Supply chain
Links to other companies, as recorded in our map from filings and announcements. A news event that hits one of them can reach Shukra Medtech Limited through this map.
No supply-chain links recorded for this company yet.
8 · News & documents
News and what it reaches
Filings and news about Shukra Medtech Limited, and bigger events that reach it through its owners, rivals, customers or suppliers. Newest first. Open one to see how the effect spreads.
No recent news or filings for this company.
Documents
Earnings calls, results presentations and annual reports, straight from the company and the exchanges.
No documents on record yet.
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.